Based on the aggregated intelligence of 170,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Cubist Pharmaceuticals (Nasdaq: CBST) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Cubist's business and see what CAPS investors are saying about the stock right now.

Cubist facts

Headquarters (Founded) Lexington, Mass. (1992)
Market Cap $2.1 billion
Industry Biotechnology
Trailing-12-Month Revenue $654.9 million
Management

CEO Michael Bonney

CFO David McGirr

Return on Equity (Average, Past 3 Years) 30%
Cash/Debt $900.7 million / $440.3 million
Competitors

Merck (NYSE: MRK)

Novartis (NYSE: NVS)

Pfizer (NYSE: PFE)

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 95% of the 336 members who have rated Cubist believe the stock will outperform the S&P 500 going forward. These bulls include gopyerk and All-Star PDTBiotech, who is ranked in the top 10% of our community.

A couple of months ago, gopyerk listed several of Cubist's positives: "Some great buzz about this company right now. Good clinicals taking place, nice earnings and some great growth potential. I like this for the long term."

Over the next five years, in fact, Cubist is expected to grow its bottom line at a solid rate of 12.1%. That's faster than much larger drug stocks like Merck (4.2%), Novartis (4%), and Pfizer (2.8%).

CAPS All-Star PDTBiotech expands on the Cubist outperform argument:

*Rumored offer by Shire is probably legit, and will stir up BD execs at many other companies to take a peek. ...

*Cubicin offers a way to buy revenues over a stretch of time when many companies will have a gap due to the patent cliff (cubicin IP expires mid-2016).

*Lots of upside to this company, including a seasoned ID sales force, some interesting pipeline products, and profitability.

What do you think about Cubist, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Motley Fool newsletter services have recommended buying shares of Novartis and Pfizer. Try any of our Foolish newsletter services free for 30 days.

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.